Ventyx Biosciences Inc VTYX

$14.00 +0.02 (0.14%)

Valuation

Market cap
1,004,654,000
Revenue TTM
$0
Net income TTM
$-135,120,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
5,448,800
Avg volume
4,041,894
Day's range
$13.99 – $14.00
Shares out
71,761,000
Stochastic %K
100%
Beta
1.26
Analysts
Hold
Price target
$13.44

Price

Company profile

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyro...

Show more

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in a Phase 2a trial for patients with early Parkinson's disease and is in a Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. As of March 4, 2026, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company.

Industry
Biotechnology
Sector
Healthcare
Phone
760-407-6511
Website
https://ventyxbio.com
Address
12790 El Camino Real, Suite 200, San Diego, United States

Latest news

Stocktwits

TheRealShortSqueezy Sep 3, 12:12 PM
🚨 $MDCX : MAJOR PFIZER DEAL JUST DROPPED Medicus Pharma just entered into a Co-Development & License Agreement with Pfizer for CD228V, an early-stage antibody-drug conjugate targeting CD228. 🔹 Exclusive worldwide license to develop and commercialize CD228V 🔹 Pfizer remains involved in the program and is providing $2M in development funding 🔹 Pfizer has the option to fund all or part of development starting with the first pivotal trial 🔹 Medicus retains control over development, manufacturing, regulatory approval and commercialization 🔹 Agreement includes more than $1 BILLION in potential development, regulatory and sales milestones 🔹 Pfizer is also eligible for low double-digit royalties on future net sales This adds an entirely new oncology asset to the MDCX pipeline with Pfizer remaining directly involved in its development. SECTOR PEERS: $CRNX $ARQT $IMVT $VTYX
0 replies
TheRealShortSqueezy Sep 3, 12:11 PM
$MDCX : MULTIPLE CATALYSTS LINING UP Medicus Pharma is a clinical stage biotech developing next-generation treatments for skin cancers and hormone related diseases, led by its SkinJect and Teverelix platforms. 🔹 SkinJect: FDA cleared its NDA enabling registrational study in Gorlin Syndrome. 🔹 Phase 2 data showed 64% clinical clearance 🔹 Teverelix: Phase 2 AUR trial optimized to roughly 126 patients vs. 390 previously planned following FDA feedback. 🔹 $25.2M in cash reported at June 30. 🔜 UPCOMING CATALYSTS • Initiation and enrollment of the SkinJect NDA-enabling registrational trial • Advancement of the Teverelix Phase 2 AUR program • Further development in high cardiovascular risk prostate cancer 💰 With SkinJect and Teverelix targeting multiple high value indications, MDCX is building a pipeline addressing an estimated $8 BILLION combined market opportunity. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyMDCX SECTOR PEERS: $CRMD $CRNX $ARQT $VTYX
0 replies
supertech1 Mar 9, 2:27 PM
$VTYX what’s going on …should I get rid of it?
0 replies
stockbuyer1234 Mar 6, 12:29 PM
$VTYX I still see the march call options on my Schwabb.Did they close the transaction?
4 replies
ians Mar 4, 7:16 PM
$VTYX $VKTX CONGRATS to LT shareholders. 👍 LLY just knows how to pick em early. Wish we could have demanded more but mgmt had no bargaining power w/o a white knight in the form of SNY. 🤷‍♂️ Nonetheless, I was correct VTYX turned out to be the next VKTX. Just didn't think it would get taken out sooner than VKTX. The ? Now is which BP will BO VKTX & for how much 🤔☘️💎 https://stocktwits.com/ians/message/586903018
0 replies
Viktor4o Mar 4, 12:38 PM
$VTYX How long its been halted for?
1 replies
NorthStarStats Mar 4, 10:52 AM
Market is full of failed breakout and rug pulls. Be careful. From the scanner: $IDYA Score: 98.00, $TGT Score: 73.00, $DAY Score: 70.00, $VTYX Score: 70, $RTX Score: 68.00
2 replies
FreeBeerTomorrow Mar 4, 8:30 AM
$VTYX VTYX- ​Acquisition Approval: Shareholders officially approved the merger with Eli Lilly on March 3, 2026. ​Merger Details: Eli Lilly is acquiring VTYX for $14.00 per share in an all-cash deal. ​What Happens to the Stock: Once the merger is finalized (expected in the first half of 2026), VTYX will stop trading on the NASDAQ and become a wholly-owned subsidiary of Eli Lilly.
0 replies